JUNS (Jupiter Neurosciences) Enterprise Value: $12.60 Mil (As of Jun. 30, 2026) ***


JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.21
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences Enterprise Value?

Jupiter Neurosciences JUNS -25.00% 4 Enterprise Value is $12.60 Mil as of Jun. 30, 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jupiter Neurosciences's Enterprise Value is $12.60 Mil. Jupiter Neurosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.00 Mil. Therefore, Jupiter Neurosciences's EV-to-EBIT ratio for today is -1.40.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Jupiter Neurosciences's Enterprise Value is $12.60 Mil. Jupiter Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.00 Mil. Therefore, Jupiter Neurosciences's EV-to-EBITDA ratio for today is -1.40.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Jupiter Neurosciences's Enterprise Value is $12.60 Mil. Jupiter Neurosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.04 Mil. Therefore, Jupiter Neurosciences's EV-to-Revenue ratio for today is 307.24.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Jupiter Neurosciences's Enterprise Value is $12.60 Mil. Jupiter Neurosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.78 Mil. Therefore, Jupiter Neurosciences's EV-to-OCF ratio for today is -2.18.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Jupiter Neurosciences's Enterprise Value is $12.60 Mil. Jupiter Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.78 Mil. Therefore, Jupiter Neurosciences's EV-to-FCF ratio for today is -2.18.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Jupiter Neurosciences  (NAS:JUNS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Jupiter Neurosciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12.597/-8.995
=-1.40

Jupiter Neurosciences's current Enterprise Value is $12.60 Mil.
Jupiter Neurosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.00 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Jupiter Neurosciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=12.597/-8.995
=-1.40

Jupiter Neurosciences's current Enterprise Value is $12.60 Mil.
Jupiter Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.00 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Jupiter Neurosciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=12.597/0.041
=307.24

Jupiter Neurosciences's current Enterprise Value is $12.60 Mil.
Jupiter Neurosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Jupiter Neurosciences's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=12.597/-5.782
=-2.18

Jupiter Neurosciences's current Enterprise Value is $12.60 Mil.
Jupiter Neurosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.78 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Jupiter Neurosciences's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=12.597/-5.782
=-2.18

Jupiter Neurosciences's current Enterprise Value is $12.60 Mil.
Jupiter Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jupiter Neurosciences Enterprise Value Related Terms


Jupiter Neurosciences Enterprise Value Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences Enterprise Value Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial 0.00 0.00 0.00 350.66 36.66

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.69 33.84 59.82 36.66 16.12

JUNS vs ZEOX, LEXX, GDTC: Enterprise Value Comparison

For the Biotechnology subindustry, Jupiter Neurosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jupiter Neurosciences Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Jupiter Neurosciences's Enterprise Value falls into.


JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Jupiter Neurosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Jupiter Neurosciences's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $12.60 Mil mean?
Jupiter Neurosciences (JUNS) has a Enterprise Value of $12.60 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' Enterprise Value too high?
Jupiter Neurosciences' current Enterprise Value is $12.60 Mil. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Enterprise Value compare to ZEOX and LEXX?
Jupiter Neurosciences' Enterprise Value of $12.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Enterprise Value is $12.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Enterprise Value of $12.60 Mil. The current Enterprise Value is $12.60 Mil. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Enterprise Value is $12.60 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price